-
Cell Free DNA Analysis And Circulating Tumor Cell Characterization In Metastatic Breast Cancer
Rochester, MN
The objective of this study is to provide preliminary data to support the development of selected technologies for the efficient and reliable analyses of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in the setting of metastatic breast cancer.
-
CfDNA With Natera
Rochester, MN
The purpose of this study is to collect blood and tumor tissue from esophageal cancer patients in order to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
-
Measuring Cell Free DNA During The Course Of Treatment For Esophageal Cancer As A Marker Of Response And Recurrence
Rochester, MN
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
-
A Study To Analyze Isolation, Activation And Expansion Of Mutation Reactive T-cells
Rochester, MN
The purpose of this study is to examine the ease and practicality of extracting central memory T-cells and the potential for their activation and ability to recognize tumor antigens and target lung cancer cells for destruction. Circulating cell-free DNA (cfDNA) from the plasma will be extracted and sequenced to identify somatic mutations that were exposed to the T-cells.
-
Donor-derived Cell-free DNA Testing in Kidney Transplant Recipients on Reduced Immunosuppression
Scottsdale/Phoenix, AZ
The purpose of this study is to determine the incidence of biopsy proven acute rejections detected due to elevated dd-cfDNA independent of change in serum creatinine, to determine incidence of DeNovo Donor specific antibody (DSA) or increase in preexisting DSA’s in presence of elevated dd-cfDNA, and to determine the association of elevated dd-cfDNA with progression of chronic changes in surveillance biopsies.
-
Development Of Non-invasive Cell-free DNA To Supplant Invasive Biopsy In Heart Transplantation
Jacksonville, FL
The purpose of this study is to describe the association between Prospera dd-cfDNA measures and other diagnostic tests used to detect heart allograft rejection and/or njury, including histology, echocardiography and DSA, in the first post-transplant year. Additionally, to inform rates of clinical outcomes in a contemporary cohort of adult heart transplant recipients to determine power for a future randomized, controlled clinical trial.